Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
11 Janeiro 2024 - 6:07PM
Business Wire
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical
company (the “Company”), announced that Alan H. Auerbach, Chairman,
Chief Executive Officer, President and Founder of Puma, will
provide an overview of the Company on January 18, 2024 at the
virtual B. Riley Securities 4th Annual Oncology Conference:
Tumor-ow’s Titans – Finding Value in (Near-) Commercial Oncology
Companies.
For access to Mr. Auerbach’s live presentation at 2:00 p.m. ET
on January 18, please contact your B. Riley representative. A
replay of the presentation will be available on Puma’s website
after 5:00 p.m. ET at https://www.pumabiotechnology.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a
focus on the development and commercialization of innovative
products to enhance cancer care. Puma in-licensed the global
development and commercialization rights to PB272 (neratinib,
oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral
was approved by the U.S. Food and Drug Administration in 2017 for
the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, following adjuvant
trastuzumab-based therapy, and is marketed in the United States as
NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also
approved by the FDA in combination with capecitabine for the
treatment of adult patients with advanced or metastatic
HER2-positive breast cancer who have received two or more prior
anti-HER2-based regimens in the metastatic setting. NERLYNX was
granted marketing authorization by the European Commission in 2018
for the extended adjuvant treatment of adult patients with early
stage hormone receptor-positive HER2-overexpressed/amplified breast
cancer and who are less than one year from completion of prior
adjuvant trastuzumab-based therapy. NERLYNX is a registered
trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license
agreement for the development and commercialization of the
anti-cancer drug alisertib, a selective, small molecule, orally
administered inhibitor of aurora kinase A. Initially, Puma intends
to focus the development of alisertib on the treatment of small
cell lung cancer and breast cancer.
Further information about Puma Biotechnology may be found at
https://www.pumabiotechnology.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111330386/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc.,
+1 424 248 6500 info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Puma Biotechnology (NASDAQ:PBYI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Puma Biotechnology (NASDAQ:PBYI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024